CFTR and cystic fibrosis: The prospect that multiple key CF phenotypes can be addressed by HDAC6 inhibition is important for patients with CFTR mutations not currently responsive to potentiator and corrector therapies, or to even augment CFTR-targeted therapies to improve inflammation and infection management.